Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition

向 Realbotix LLC 提供 250 万美元的初始预付款，以支持其增长和营运资金；该无息融资安排在待决收购完成时自动取消并全部解除

CINCINNATI, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE) --

俄亥俄州辛辛那提，2026年9月14日（环球电讯社）——

Onconetix, Inc. (Nasdaq: ONCO) ('Onconetix' or the 'Company') today announced that it has provided a strategic bridge financing facility of up to $5,000,000 to Realbotix LLC ('Realbotix'), the target of its previously announced pending acquisition, to support Realbotix's growth and working capital needs while the parties advance toward closing of the acquisition.

Onconetix, Inc.（纳斯达克股票代码：ONCO）（“Onconetix”或“公司”）今日宣布，已向其实体收购目标Realbotix LLC（“Realbotix”）提供一笔高达500万美元的战略过桥融资安排，以支持Realbotix的增长和营运资金需求，同时双方正推进完成该收购交易。

The financing was provided in connection with the Share Exchange Agreement between the two companies, announced on February 12, 2026..

该融资与两家公司于2026年2月12日宣布的股份交换协议相关。

The facility provides for an aggregate principal amount of up to $5,000,000, with an initial advance of $2,500,000.

该融资设施提供总额最高达5,000,000美元的本金，首次预付款为2,500,000美元。

The facility is non-interest bearing prior to the closing of the Share Exchange Agreement. Upon closing of the acquisition, the facility and all obligations thereunder will be automatically cancelled and discharged in full. In addition, the cash required at closing of the acquisitions will be reduced by the total principal advanced under the facility plus an additional $500,000.

在《股份交换协议》交割前，该融资不计息。在收购交割时，该融资及其项下所有义务将自动取消并全部解除。此外，收购交割时所需的现金将扣除该融资项下已发放的本金总额以及额外的50万美元。

If the Share Exchange Agreement is terminated, interest accrues at 12% per annum from the date of termination. A description of the Note is included in Onconetix’s Current Report on Form 8-K filed with the SEC on [DATE], 2026. The full text of the Note is filed as an exhibit to that report and is available at .

如果《股份交换协议》终止，则自终止之日起按年利率12%累计利息。关于该票据的描述包含在Onconetix于2026年[日期]向美国证券交易委员会（SEC）提交的8-K表格当前报告中。该票据的全文作为该报告的附件提交，并可在获取。

www.sec.gov

www.sec.gov

.

。

As previously announced on February 12, 2026, Onconetix entered into the Share Exchange Agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions..

正如2026年2月12日此前公告，Onconetix签订了股份交换协议，以全股票交易方式收购Realbotix LLC全部已发行和流通的股权。预计合并后的公司将在交易完成后于纳斯达克上市，但该交易需获得Onconetix股东批准、必要的监管批准以及其他交割条件的满足。

This communication is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information.

本沟通内容仅供信息参考。投资者需谨慎，切勿过度依赖前瞻性或预测性信息。

About Onconetix, Inc.

关于 Onconetix 公司

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S.

Onconetix, Inc.（纳斯达克股票代码：ONCO）是一家处于商业化阶段的生物技术公司，专注于创新肿瘤解决方案的研发与商业化。Onconetix 拥有 Proclarix®，这是一种由 Proteomedix 最初开发的前列腺癌体外诊断检测产品，已根据欧盟体外诊断医疗器械法规（IVDR）获准在欧盟销售，公司预计该产品将在美国市场推出。

as a lab developed test through its license agreement with Labcorp. For more information, visit .

作为通过与Labcorp的许可协议开发的实验室研发检测项目。更多信息，请访问。

www.onconetix.com

www.onconetix.com

.

。

About Realbotix LLC

关于 Realbotix LLC

Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement.

Realbotix LLC 是 Realbotix Corp.（TSX-V: XBOT；法兰克福：76M0.F；OTC: XBOTF）的全资子公司，也是 Onconetix 待完成收购的目标公司。Realbotix LLC 开发由人工智能驱动的人形机器人，旨在为企业和消费者环境提供人际互动体验。Realbotix 的产品在美国制造，其拥有专利的人工智能和机器人技术能够实现逼真的表情、动作、视觉和社会交互能力。

For more information, visit .

欲了解更多信息，请访问。

www.realbotix.ai

www.realbotix.ai

.

。

Additional Information and Where to Find It

附加信息及获取途径

In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction.

就Realbotix与Onconetix之间拟议的交易而言，Onconetix打算向美国证券交易委员会（SEC）提交一份S-4表格注册声明（“注册声明”），以登记Onconetix因该拟议交易而将发行的普通股。该注册声明将包括Onconetix的委托声明书和招股说明书（“委托声明书/招股说明书”），且Realbotix和Onconetix均可能就拟议交易向SEC提交其他相关文件。

After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC.

在注册声明生效后，最终的代理声明/招股说明书将发送给Onconetix的股东，以寻求他们对拟议交易的批准。这并不替代Realbotix或Onconetix已向或将向美国证券交易委员会（SEC）提交的注册声明、代理声明/招股说明书或任何其他相关文件。

BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS..

在作出任何投票或投资决策之前，Onconetix 的投资者和股东被敦促仔细并完整地阅读与拟议交易相关的注册声明和代理声明/招股说明书，以及任何其他相关文件，并在这些文件的修订版或补充文件（如有）可供查阅时予以阅读，因为这些文件将包含有关 Realbotix、Onconetix、拟议交易及相关事项的重要信息。

A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available, at the SEC’s website at

注册声明、代理声明/招股说明书，以及 Realbotix 和 Onconetix 向美国证券交易委员会（SEC）提交的其他相关文件，可在其发布后于美国证券交易委员会网站免费获取，网址为

www.sec.gov

www.sec.gov

. The information on Realbotix or Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

Realbotix 或 Onconetix 各自网站上的信息不构成、也不应被视为本通讯的一部分，亦不被纳入任一公司向美国证券交易委员会（SEC）提交的其他文件中。

Participants in the Solicitation

招标参与者

Realbotix, Onconetix and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed from time to time with the SEC.

Realbotix、Onconetix 以及它们各自的某些董事、高级管理人员和员工可能被视为与拟议交易相关的代理权征集的参与者。有关 Onconetix 董事和高级管理人员的信息、他们对 Onconetix 普通股的所有权，以及 Onconetix 与关联方之间的交易，均载于 2026 年 3 月 13 日向美国证券交易委员会（SEC）提交的 10-K 表格年度报告，以及可能不时向 SEC 提交的其他文件中。

Additional information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC.

关于Realbotix和Onconetix的董事及高级管理人员，以及可能被视为参与就拟议交易向Onconetix股东征集投票权的其他人员的更多信息，及其直接和间接利益的描述，将包含在与拟议交易相关的代理声明/招股说明书或其他相关材料中，这些材料将提交给美国证券交易委员会（SEC）。

These documents may be obtained free of charge, when they become available, at the SEC’s website at .

这些文件在发布后，可在美国证券交易委员会（SEC）网站免费获取。

www.sec.gov

www.sec.gov

and from Onconetix using the sources indicated above.

并使用上述来源从Onconetix获取。

No Offer or Solicitation

不构成要约或招揽

This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

本沟通内容仅供信息参考，无意构成且不构成出售任何证券的要约或购买或出售任何证券的要约之招揽，亦不构成对任何委托书、投票或批准的招揽；在任何司法管辖区，若根据该司法管辖区的证券法在注册或资格认定之前进行此类要约、招揽或出售属违法，则不得在该司法管辖区进行任何证券销售。

No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act..

不得通过招股说明书以外的任何方式发出证券要约，且该招股说明书须符合《证券法》第10条的要求；或者在豁免于《证券法》登记要求的交易中进行。

Forward-Looking Statements

前瞻性陈述

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others.

本新闻稿中的某些陈述属于1995年《私人证券诉讼改革法》所定义的前瞻性陈述。这些陈述可通过使用“预期”、“相信”、“预测”、“估计”、“期望”和“打算”等前瞻性词汇加以识别。

These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.

这些前瞻性陈述（包括但不限于本文所述拟议交易可能产生的预期益处和机会）基于Onconetix当前的预期，实际结果可能存在重大差异。存在多种因素可能导致实际事件与此类前瞻性陈述所指示的情况产生重大差异。

These factors include, but are not limited to, the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or take longer to complete than ant.

这些因素包括但不限于：发生任何可能导致一方或双方有权终止股份交换协议的事件、变化或其他情况；由于未能及时或完全满足交割条件（包括未能及时获得Onconetix股东对拟议交易的批准，如果最终能获得的话），拟议交易可能无法按预期完成或根本无法完成的风险；在拟议交易完成之前，Onconetix继续在纳斯达克上市的相关风险；可能对Realbotix、Onconetix或合并后的公司提起的任何法律诉讼的结果；拟议交易的预期收益可能无法按预期实现或根本无法实现的可能性；合并后公司的愿景、目标和战略轨迹可能无法及时实现或根本无法实现的可能性；以及拟议交易的成本可能高于预期或完成时间可能长于预期的可能性。

Investor and Media Contact:

投资者与媒体联系人：

Onconetix, Inc.

Onconetix公司

201 E. Fifth Street, Suite 1900

东第五街201号，1900室

Cincinnati, OH 45202

俄亥俄州辛辛那提 45202

Phone: (513) 620-4101

电话：(513) 620-4101

Email:

电子邮件：

investors@onconetix.com

investors@onconetix.com